BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 1118487)

  • 41. Immunological changes in cancer patients receiving BCG.
    Cochran AJ; Mackie RM; Jackson AM; Ogg LJ; Ross CE
    Dev Biol Stand; 1977 Apr 13-15; 38():441-8. PubMed ID: 608535
    [TBL] [Abstract][Full Text] [Related]  

  • 42. BCG immunotherapy as a systemic adjunct to surgery in malignant melanoma.
    Morton DL; Eilber FR; Holmes EC; Sparks FC; Ramming K
    Med Clin North Am; 1976 May; 60(3):431-9. PubMed ID: 1271888
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Delayed cutaneous sensitivity reactions to extracts of autologous malignant melanoma: a second look.
    Bluming AZ; Vogel CL; Ziegler JL; Kiryabwire JW
    J Natl Cancer Inst; 1972 Jan; 48(1):17-24. PubMed ID: 4652371
    [No Abstract]   [Full Text] [Related]  

  • 44. BCG in cancer therapy: theoretical bases of immunotherapy.
    Dodd MJ
    Am J Nurs; 1979 Feb; 79(2):310-4. PubMed ID: 311587
    [No Abstract]   [Full Text] [Related]  

  • 45. Re-inventing intratumoral immunotherapy for melanoma.
    Triozzi PL; Tuthill RJ; Borden E
    Immunotherapy; 2011 May; 3(5):653-71. PubMed ID: 21554094
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Influence of preexisting tumor immunity on Bacillus Calmette-Guérin immunotherapy of guinea pigs with both regional and disseminated tumor.
    Jessup JM; Riggs CW; Hanna MG
    Cancer Res; 1977 Aug; 37(8 Pt 1):2565-73. PubMed ID: 872084
    [No Abstract]   [Full Text] [Related]  

  • 47. B.C.G. in malignant melanoma.
    Baker MA; Taub RN
    Lancet; 1973 May; 1(7812):1117-8. PubMed ID: 4122031
    [No Abstract]   [Full Text] [Related]  

  • 48. Successful transurethral intralesional BCG therapy of a bladder melanoma.
    deKernion JB; Golub SH; Gupta RK; Silverstein M; Morton DL
    Cancer; 1975 Nov; 36(5):1662-7. PubMed ID: 1192356
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Immunotherapy of malignant melanomas].
    Macher E
    Haematol Blood Transfus; 1978; 21():285-91. PubMed ID: 738638
    [No Abstract]   [Full Text] [Related]  

  • 50. [Intralesion BCG vaccine therapy in cutaneous melanoma metastasis].
    Wolf M; Menzel W
    Dermatol Monatsschr; 1978 Sep; 164(9):671-2. PubMed ID: 710658
    [No Abstract]   [Full Text] [Related]  

  • 51. Experience with BCG adjuvant immunotherapy in stage II malignant melanoma.
    Peter HH; Deutschmann EM; Schultheis W; Deicher H
    Dev Biol Stand; 1977 Apr 13-15; 38():537-40. PubMed ID: 344106
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Immunologic aspects of the treatment of melanoma].
    Pawlowska EM
    Pol Tyg Lek; 1977 Jun; 32(24):939-41. PubMed ID: 882435
    [No Abstract]   [Full Text] [Related]  

  • 53. Results of administering B.C.G. to patients with melanoma.
    Grant RM; Mackie R; Cochran AJ; Murray EL; Hoyle D; Ross C
    Lancet; 1974 Nov; 2(7889):1096-100. PubMed ID: 4139404
    [No Abstract]   [Full Text] [Related]  

  • 54. Regression of pulmonary metastatic disease associated with intralesional BCG therapy of intracutaneous melanoma metastases.
    Mastrangelo MJ; Bellet RE; Berkelhammer J; Clark WH
    Cancer; 1975 Oct; 36(4):1305-8. PubMed ID: 1175129
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immunologic effects of BCG in patients with malignant melanoma: specific evidence for stimulation of the 'secondary' immune response.
    Chess L; Bock GN; Ungaro PC; Buchholz DH; Mardiney MR
    J Natl Cancer Inst; 1973 Jul; 51(1):57-65. PubMed ID: 4720886
    [No Abstract]   [Full Text] [Related]  

  • 56. BCG stimulation of immune responsiveness in patients with malignant melanoma. Preliminary report.
    Gutterman J; Mavligit G; McBride C; Frei E; Hersh EM
    Cancer; 1973 Aug; 32(2):321-7. PubMed ID: 4722915
    [No Abstract]   [Full Text] [Related]  

  • 57. Viral oncolysate in the management of malignant melanoma. I. Preparation of the oncolysate and measurement of immunologic responses.
    Cassel WA; Murray DR; Torbin AH; Olkowski ZL; Moore ME
    Cancer; 1977 Aug; 40(2):672-9. PubMed ID: 196739
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Malignant melanoma.
    Moore GE; Gerner RE
    Surg Gynecol Obstet; 1971 Mar; 132(3):427-36. PubMed ID: 5546295
    [No Abstract]   [Full Text] [Related]  

  • 59. Immunologic defects in melanoma patients: lack of effect of BCG therapy.
    Gersten MJ; Hadden EM; Kaplan MH; Pinsky CM; Armstrong D; Hadden JW
    Clin Bull; 1977; 7(2):63-9. PubMed ID: 902403
    [No Abstract]   [Full Text] [Related]  

  • 60. [Immunology and melanoma. Theoretical-experimental observations].
    Jurado A; Céspedes de Gómez M
    Alergia; 1981 Oct; 28(4):145-72. PubMed ID: 7332071
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.